Engineered immune cells take on childhood leukemia in early trial
NCT ID NCT02650414
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study tests a one-time treatment using the patient's own immune cells, modified to target a protein called CD22 on leukemia cells. It is for children and young adults whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The main goals are to see if the therapy is safe and possible to make, while also checking if it can put the cancer into remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LEUKEMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot